Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-12-26
2006-12-26
Canella, Karen A. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007400, C435S007920, C435S023000, C436S064000, C436S536000
Reexamination Certificate
active
07153660
ABSTRACT:
Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs.
REFERENCES:
patent: 6037138 (2000-03-01), Moses et al.
patent: 6610484 (2003-08-01), Hung
patent: WO 93/20447 (1993-10-01), None
patent: WO 97/41441 (1997-11-01), None
patent: WO 97/41441 (1997-11-01), None
The abstract of Black et al (Clinical Cancer Research, Feb. 2000, vol. 6, pp. 467-473).
Kolkenbrock et al (Biological Chemistry, 1996, vol. 377, pp. 529-533).
Stoesz et al (International Journal of Cancer, 1998, vol. 79, pp. 565-572).
Kerr and Thorpe (Immunochemistry LabFax, 1994, pp. 115-122).
Tsuda et al (FEBS Letters, 1993, vol. 319, pp. 35-39).
Abstract of Monier et al (Clinica Chimica Acta, Sep. 2000, vol. 299, pp. 11-23).
Kjeldsen et al (Journal of Biological Chemistry, 1993, vol. 268, pp. 10425-10432).
Baker, T. et al. “Serum metalloproteinases and their inhibitors: markers for malignant potential.”Br J Cancer. Sep. 1994; 70(3):506-12.
Garbisa, S. et al. “Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy.”Cancer Res. Aug. 15, 1992; 52(16):4548-9.
Kleiner, D.E. et al. “Matrix metalloproteinases and metastasis.”Cancer Chemother. Pharmacol. 1999; 43 Suppl:S42-51.
Lochter, A. et al. “The significance of matrix metalloproteinases during early stages of tumor progression.”Ann N Y Acad Sci. Oct. 23, 1998; 857:180-93.
Monier, F. et al. “Gelatinase isoforms in urine from bladder cancer patients”Clin. Chim. Acta. Sep. 2000; 299 (1-2):11-23.
Moses, M. et al. “Increased incidence of matrix metalloproteinases in urine of cancer patients”Cancer Res. Apr. 1, 1998; 58(7): 1395-9.
Nakajima, M. et al. “Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762 NF mammary adenocarcinoma.”Cancer Res. Dec. 1, 1993; 53(23):5802-7.
Yan, Li, et al. “The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL”J Biol Chem. Oct. 5, 2001;276(40):37258-65.
Zucker, S. et al. “Plasma assay of matrix metalloproteinases (MMPs) and MMP inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment.” Ann NY Acad. Sci. Sep. 6, 1994; 732:248-62.
Moses Marsha A.
Yan Li
Canella Karen A.
Children's Medical Center Corporation
Nixon & Peabody LLP
LandOfFree
Non-invasive enzyme screen for tissue remodelling-associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-invasive enzyme screen for tissue remodelling-associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-invasive enzyme screen for tissue remodelling-associated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3710004